A new mechanism of acid suppressant drug walker, approved to enter China!

Takeda China yesterday announced a new mechanism of acid suppressive drug Walker ® (common name: fumarate vonolason tablets), which has been officially approved by the National Drug Administration (nmpa) to enter China, and approved the indications for the treatment of reflux esophagitis (RE) Walker ® (funorasheng fumarate tablets) is the first potassium competitive acid blocker (p-cab) approved to enter the Chinese market Clinical data show that it has the characteristics of the first full effect 1, long-lasting acid suppression 2 and easy to take 3 Walker ® (fumarate vonolason tablets) is approved for marketing in China, providing a new choice for clinical medication of reflux esophagitis treatment, which will significantly improve the quality of life of patients with reflux esophagitis At present, the main purpose of treatment for reflux esophagitis is to reduce symptoms, heal mucosa and maintain the relief of reflux esophagitis, prevent related complications and improve the quality of life related to health As a new mechanism of acid suppressing drug, Walker (vonolason fumarate tablets) can block the K + channel of H +, K + - ATPase, competitively block the combination of K + and the enzyme, and can stay in the gastric wall cells for a long time, so as to quickly inhibit the secretion of gastric acid, providing a new treatment option for patients with reflux esophagitis Vonolasang fumarate tablets were launched in Japan in February 2015 for the treatment of acid related diseases, including reflux esophagitis, gastric ulcer, duodenal ulcer, prevention of recurrence of gastric ulcer or duodenal ulcer during the treatment with low-dose aspirin or non steroidal anti-inflammatory drugs, and eradication of Helicobacter pylori In March 2018, the drug review center of the State Drug Administration officially accepted the listing application of Walker ® (vonolason fumarate tablets), and officially approved the listing on December 18, 2019 Mr Shan Guohong, President of Takeda China, said: "thank you very much for the approval of the State Drug Administration to enter the Chinese market The approval of Walker ® fully demonstrates the Chinese government's determination to deepen medical reform and accelerate the introduction of innovative drugs to improve people's healthy life Adhering to the concept of patient first, Takeda will continue to be committed to the research and development of highly innovative drugs and breakthrough therapies, bring more innovative drugs in the field of digestion into China faster, and escort the healthy life and a better future of the Chinese people " Adorable adorable